PM Philip Morris International Inc.

Philip Morris International to Host Webcast of 2024 Third-Quarter and First Nine-Months Results

Regulatory News:

Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at on Tuesday, October 22, 2024, at 9:00 a.m. ET, to discuss its 2024 third-quarter and first nine-months results, which will be issued at approximately 7:00 a.m. ET the same day.

The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI’s financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode.

The webcast may also be accessed on mobile devices by downloading PMI’s Investor Relations App at .

The webcast recording and the slides and script will be available at . The recording will be available until 5:00 p.m. ET on Friday, November 22, 2024.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products and renewal applications for these products are presently pending before the FDA. As of June 30, 2024, PMI's smoke-free products were available for sale in 90 markets, and PMI estimates that 36.5 million adults around the world use PMI's smoke-free products. Smoke-free business accounted for approximately 38% of PMI’s total first-half 2024 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. "PMI" refers to Philip Morris International Inc. and its subsidiaries. For more information, please visit and .

EN
15/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Philip Morris International Inc.

Philip Morris International Inc: 1 director

A director at Philip Morris International Inc sold 10,000 shares at 132.480USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

 PRESS RELEASE

Philip Morris International Reports 2024 Third-Quarter & First Nine-Mo...

STAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc. (PMI) (NYSE: PM) today announces its 2024 third-quarter and first nine-months results.1 “In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share,” said Jacek Olczak, Chief Executive Officer. “This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance.” “As a result of our strong year-to-date delivery, we are raisin...

 PRESS RELEASE

Court-Appointed Mediator Proposes CCAA Plan to Resolve Tobacco Product...

STAMFORD, CT--(BUSINESS WIRE)-- Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH’s Companies’ Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantially similar proposed plans ...

 PRESS RELEASE

Philip Morris International to Host Webcast of 2024 Third-Quarter and ...

STAMFORD, CT--(BUSINESS WIRE)-- Regulatory News: Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at on Tuesday, October 22, 2024, at 9:00 a.m. ET, to discuss its 2024 third-quarter and first nine-months results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI’s financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading P...

 PRESS RELEASE

Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris Internation...

STAMFORD, CT--(BUSINESS WIRE)-- Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE: PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma’s inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The tr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch